⌘K

07:00:00·1570d

PRReleasevia Quantisnow

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD

ByQuantisnow·Wall Street's wire, on your screen.

BIIB· Biogen Inc.SAGE· Sage Therapeutics Inc.

Health Care

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD | Quantisnow